These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 22374861)

  • 1. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
    Saccullo G; Malato A; Raso S; Santoro M; Zammit V; Casuccio A; Siragusa S
    Am J Hematol; 2012 Apr; 87(4):388-91. PubMed ID: 22374861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.
    Dentali F; Pignatelli P; Malato A; Poli D; Di Minno MN; Di Gennaro L; Rancan E; Pastori D; Grifoni E; Squizzato A; Siragusa S; Di Minno G; Ageno W
    Am J Hematol; 2012 Apr; 87(4):384-7. PubMed ID: 22367852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin.
    Malato A; Saccullo G; Lo Coco L; Caramazza D; Abbene I; Pizzo G; Casuccio A; Siragusa S
    J Thromb Haemost; 2010 Jan; 8(1):107-13. PubMed ID: 19817996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
    Kovacs MJ; Kearon C; Rodger M; Anderson DR; Turpie AG; Bates SM; Desjardins L; Douketis J; Kahn SR; Solymoss S; Wells PS
    Circulation; 2004 Sep; 110(12):1658-63. PubMed ID: 15364803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD; Johnson JA; Turpie AG
    Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement.
    Meurin P; Tabet JY; Weber H; Renaud N; Ben Driss A
    Circulation; 2006 Jan; 113(4):564-9. PubMed ID: 16449734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER).
    Omran H; Bauersachs R; Rübenacker S; Goss F; Hammerstingl C
    Thromb Haemost; 2012 Jul; 108(1):65-73. PubMed ID: 22534746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study.
    Pengo V; Cucchini U; Denas G; Erba N; Guazzaloca G; La Rosa L; De Micheli V; Testa S; Frontoni R; Prisco D; Nante G; Iliceto S;
    Circulation; 2009 Jun; 119(22):2920-7. PubMed ID: 19470892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of thromboembolism with short-term interruption of warfarin therapy.
    Garcia DA; Regan S; Henault LE; Upadhyay A; Baker J; Othman M; Hylek EM
    Arch Intern Med; 2008 Jan; 168(1):63-9. PubMed ID: 18195197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery.
    Bucci C; Geerts WH; Sinclair A; Fremes SE
    Am J Cardiol; 2011 Feb; 107(4):591-4. PubMed ID: 21184996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation.
    Wysokinski WE; McBane RD; Daniels PR; Litin SC; Hodge DO; Dowling NF; Heit JA
    Mayo Clin Proc; 2008 Jun; 83(6):639-45. PubMed ID: 18533080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
    Hammerstingl C; Omran H
    Europace; 2011 Sep; 13(9):1304-10. PubMed ID: 21508005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early postoperative bridging anticoagulation after mechanical heart valve replacement: a systematic review and meta-analysis.
    Passaglia LG; de Barros GM; de Sousa MR
    J Thromb Haemost; 2015 Sep; 13(9):1557-67. PubMed ID: 26178802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Mismetti P; Mille D; Laporte S; Charlet V; Buchmüller-Cordier A; Jacquin JP; Fournel P; Dutrey-Dupagne C; Decousus H;
    Haematologica; 2003 Jan; 88(1):67-73. PubMed ID: 12551829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.
    Lavau-Denes S; Lacroix P; Maubon A; Preux PM; Genet D; Vénat-Bouvet L; Labourey JL; Martin J; Slaouti P; Tubiana-Mathieu N
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):65-73. PubMed ID: 23636449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism.
    Marchena PJ; Nieto JA; Guil M; García-Bragado F; Rabuñal R; Boccalon H; Trujillo-Santos J; Monreal M;
    Thromb Haemost; 2012 Jan; 107(1):37-43. PubMed ID: 22116496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.